Adipose tissue is a dynamic endocrine organ that is essential to regulation of metabolism in humans. A new approach to mental disorders led to research on involvement of adipokines in the etiology of mental disorders and mood states and their impact on the health status of psychiatric patients, as well as the effects of treatment for mental health disorders on plasma levels of adipokines. There is evidence that disturbances in adipokine secretion are important in the pathogenesis, clinical presentation and outcome of mental disorders. Admittedly leptin and adiponectin are involved in pathophysiology of depression. A lot of disturbances in secretion and plasma levels of adipokines are observed in eating disorders with a significant impact on the symptoms and course of a disease. It is still a question whether observed dysregulation of adipokines secretion are primary or secondary. Moreover findings in this area are somewhat inconsistent, owing to differences in patient age, sex, socioeconomic status, smoking habits, level of physical activity, eating pathology, general health or medication. This was the rationale for our detailed investigation into the role of the endocrine functions of adipose tissue in mental disorders. It seems that we are continually at the beginning of understanding of the relation between adipose tissue and mental disorders.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

Key words: Adiponectin; Leptin; Visfatin; Resistin; Omentin; Adipsin; Eating disorders; Schizophrenia

Core tip: New approach to adipose tissue as endocrine organ developed new research fields in psychiatry. Several papers linked the well-known adipokines like leptin, adiponectin and resistin with mental disorders. But there are still a hundreds of recently discovered adipokines with possible role in mental disorders.
INTRODUCTION
This year is the twenty-year anniversary of a new approach to adipose tissue. Since the discovery of leptin in 1994, adipose tissue has been recognized as an endocrine organ and an important source of biologically active peptides called adipokines.

There is growing body of clinical evidence that adipokines play a role in various mental disorders including schizophrenia, mood disorders, anxiety disorders, post-traumatic stress disorder, eating disorders (EDs), sleep disorders, autism spectrum disorders (ASDs), attention deficit hyperactivity disorder and some neurodegenerative disorders such as Alzheimer’s disease (AD). Research on adipokines has looked at the effects of drugs used to treat mental disorders on the plasma level of adipokines, the role of adipokines in the etiology of mental disorders and mood states and their impact on other aspects of the health status of psychiatric patients. One of the most interesting and challenging areas of research is the role of adipocytes in the etiology of mental disorders. Recently clinical research has been corroborated by novel studies in animal models. Use of animal models enables us to develop a more sophisticated causal model of the role of adipocytes in normal and pathological psychological functioning. Several types of adipocyte receptor have been found in several central nervous system areas, and have been shown to affect brain function through neuroplastic processes. The findings in depth the immune theory of psychiatric diseases. Also some hypotheses tiding etiology of mental disorders and addictions in adults with disturbed adipocyte development in childhood were formulated. There are other possible mechanisms by which adipocytes may be involved in the etiology of mental disorders. At present the evidence is inconsistent, and raises new questions and suggests new topics for research. Understanding the role of adipocytes in the etiology of mental disorders might lead to new treatments and approaches to managing mental health problems. On the other side research on the role of adipokines in mental health reflects significant changes in perception of adipose tissue. Methodological problems with research in this area continue to be reflected in inconsistent results. In attempting to synthesize the findings of the various studies it is essential to consider interactions among factors such as patient age, sex, socioeconomic status, smoking habits, level of physical activity, eating pathology, general health and medication. More research is needed, particularly into the ways in which adipokines circulate around the various body fluids and compartments. This review discusses research linking selected adipokines with mental disorders.

ADIPONECTIN
Adiponectin is a 244-amino acid peptide produced in adipose tissue by mature adipocytes and is classed as an adipokine. Adiponectin was discovered independently in four different laboratories in 1995; it is also known as adipoQ, adipocyte complement-related protein with mass = 30 kDa, gelatin binding protein with mass = 28 kDa and adipose most abundant gene transcript 1 (apM1). Native adiponectin creates homotrimers that may form dimers, trimers and high molecular weight (HMW) complexes. Adiponectin interacts with adiponectin receptors (AdipoR1 and AdipoR2) and is homologous to C1q subunits and globular domains of type X and VII collagens. Both receptors are expressed in white and brown adipose tissue. AdipoR1 is expressed mainly in skeletal muscles but is also found in endothelial cells. It has high affinity for globular adiponectin and low affinity for full-length adiponectin. The complex of AdipoR1 with adiponectin activates AMP-activated protein kinase (AMPK) and promotes lipid oxidation. AdipoR2 is highly expressed in the liver and has intermediate affinity for both globular and full-length adiponectin. It increases peroxisome-proliferator-activated receptor ligand activity by reducing steatosis and enhancing insulin sensitivity through activation of AMPK. T-cadherin, an adiponectin-binding protein with high affinity for HMW adiponectin multimers is mainly expressed in the endothelium and smooth muscle.

BIOLOGICAL ROLE OF ADIPONECTIN
The biochemical effect of adiponectin partly depends on the relative high concentration of this peptide in the blood, as compared to the remaining adipokines. Adiponectin accounts for approximately 0.01% of all plasma protein. Adiponectin is mainly involved in energy homeostasis. It is exclusively secreted by adipocytes and is linked to glucose and lipid regulation. Adiponectin stimulates fatty acid oxidation, suppresses hepatic glucoseogenesis and also inhibits monocyte adhesion, macrophage transformation, proliferation and migration of smooth muscle cells into blood vessels. These metabolic and anti-inflammatory actions are closely associated with activation of AMPK and modulation of nuclear factor-B. AdipoR1 and AdipoR2 are expressed widely both in peripheral tissues and in the brain. Adiponectin plays a crucial role in several metabolic diseases. It has strong insulin-sensitizing and anti-inflammatory effects. Multiple metabolic abnormalities such as obesity, diabetes and atherosclerosis have been associated with decreased adiponectin levels. In several animal models treatment with adiponectin was shown to reverse these abnormalities, resulting in increases in fatty acid oxidation, insulin sensitivity and reductions in glucose and lipid levels.

ADIPONECTIN IN MENTAL DISORDERS
Adiponectin activity is strongly associated with metabolic disorders and energy expenditure interactions, but it has also been associated with various mental disorders such as mood disorders, anxiety disorders, eating and sleep
disorders and neurodegenerative disorders.

Decreased serum adiponectin levels have been also reported in major depressive disorders, panic disorders and schizophrenia. Serum levels of adiponectin were significantly lower in elderly patients with major depressive disorders than in non-depressed controls. Adiponectin also plays an important role in depression-related behaviors. Circulating adiponectin levels were decreased in a chronic social defeat stress model of depression; they were also inversely correlated with the social interaction ratio. Adiponectin insufficiency increased susceptibility to stress-induced depressive behaviors and impaired function of hypothalamic-pituitary-adrenal axis. Expression of AdipoR1 and AdipoR2 was high in areas of the brain involved in depressive disorders and intra-cerebral administration of adiponectin elicited antidepressant-like behavioral effects in normal-weight mice and obese diabetic mice.

Reduction in circulating adiponectin levels has been correlated with social withdrawal, which is common in psychiatric disorders such as depression and post-traumatic stress disorder. The mechanisms underlying the reduction in circulating adiponectin levels induced by social defeat are still not known, however very recent research has shown that glucocorticoid stress hormones inhibit adiponectin gene expression and secretion in vitro and in vivo. It seems reasonable to speculate that a social defeat-induced decrease in plasma adiponectin levels may be connected to a stress-induced surge in glucocorticoids.

The data on adiponectin levels in anorexia nervosa (AN) patients are inconsistent. It has been reported that adults with AN have decreased, increased or unchanged adiponectin levels. Earlier research showing that obese patients have lower total adiponectin levels suggested that adiponectin levels might be negatively correlated with body mass index (BMI). A later study assessing levels of specific isoforms of adiponectin found that percentage HMW was lower in the AN group than in controls, whereas percentage low molecular weight (LMW) was higher in the AN group. HMW and LMW were positively and negatively correlated with the BMI respectively in the sample as a whole. The observation that the level of total adiponectin was similar in the AN group and control group suggests that AN may be associated with upregulation of adiponectin production, because these patients with AN appear to have produced a similar amount of adiponectin to controls despite having fewer fat cells.

Assessments of adiponectin levels in patients with schizophrenia suggest that they are dependent on nutritional status. Elevated adiponectin levels were observed in normal-weight, drug-naïve, first-episode schizophrenia patients. In schizophrenia upregulated secretion of adiponectin has been correlated with levels of pro-inflammatory mediators; it has been suggested that inflammation is not the only reason for the increase in adiponectin secretion in schizophrenia.

Although adiponectin is involved in sleep regulation and the pathomechanism of seizures normal levels have been reported in normal-weight patients with mild sleep disorders such as parasomnia and epilepsy. Only in patients with severe sleep disorders such as obstructive sleep apnea hypopnea syndrome (OSAHS) have decreased levels of adiponectin been found, but OSAHS is associated with more serious hypoxia-related changes in the brain and frequently co-occurs with obesity.

Adiponectin abnormalities have been implicated in various metabolic disorders and may also be risk factors for the development of neurodegenerative disorders such as AD.

To date few studies have investigated the potential relationship between adiponectin and AD. One recent clinical study demonstrated that some AD patients have elevated levels of adiponectin in plasma and cerebrospinal fluid, which suggests that adiponectin may play an important role in mediating AD progression, possibly through its effects on peripheral or brain metabolism. Recent studies have shown that the adiponectin receptors AdipoR1 and AdipoR2 are expressed throughout the central nervous system. But there is still controversy as to whether adiponectin crosses the blood-brain barrier. It is likely that both adiponectin and adiponectin pathways could be targets for a new, effective treatment for AD.

LEPTIN

Leptin, a 146-amino acid peptide, is a product of the Ob(Lep) gene and is mainly synthesized by adipocytes. Leptin has also been extracted from placenta, stomach mucosa, enterocytes, liver and bone marrow. Leptin was identified in 1994 and takes its name from the Greek leptos, meaning slim, fit. It functions as a “satiety signal” and is released by fat tissue and regulate food intake regarding to total fat tissue storage. Leptin plays an important role in peripheral signaling, providing information about accumulated energy stores and thus playing a role in long-term regulation of the amount of food ingested. This adipose tissue-derived hormone modulates a complex hypothalamic network of several cooperating orexigenic and anorexigenic neuropeptides to reduce food intake and increase energy expenditure. The arcuate nucleus (ARC) is an important leptin-sensitive hub. Other hypothalamic and thalamic nuclei including the paraventricular nucleus, dorsomedial nucleus, ventromedial nucleus and lateral hypothalamic area are also direct targets of leptin.

BIOLOGICAL ACTIONS OF LEPTIN

Leptin plays a critical role as a negative regulator of food intake through specific neuronal receptors localized in hypothalamic nuclei. Leptin stimulates anorexigenic neurons expressing pro-opiomelanocortin and inhibits orexigenic pathways releasing neuropeptide Y and the melanocortin antagonist Agouti-related peptide. Leptin
LEPTIN AND MENTAL DISORDERS

In humans, both high and low levels of leptin have been associated with psychopathology. Leptin resistance accompanying obesity is supposed to influence disorders such as anxiety, depression and may affect neurocognitive functions. It is commonly believed, although there is no definitive proof, that appetite modulators also affect non-homeostatic cognitive, emotional and reward factors involved in regulation of food intake. The most common disorders associated with disturbance of metabolic state regulators are AN and bulimia nervosa (BN). AN and BN are classified as EDs of complex and still unknown etiology. AN is characterized by low leptin levels. Data on leptin levels in leptin in the BN are inconsistent; it is possible that leptin levels may be vary according to the phase of the disease or the severity of symptoms. In AN patients levels of leptin are similar to those seen in healthy controls and lower than in healthy controls. Leptin levels have been shown to correlate with BMI and leptin serum levels. This suggests that there may be a direct association between leptin concentration balance and depressive symptoms. Leptin may serve as biomarker for depression in general, or in depressed patients with altered metabolic function.

Modern research on the importance of leptin in EDs has explored its wider role, focusing on the critical role that appetite regulation and weight regulation mechanisms play in weight loss and maintenance of lean body mass. Research into early epigenic encoding of leptin-receptor interactions is another promising new area of investigation.

Early research on the role of leptin in schizophrenia explored the impact of treatment with antipsychotics on leptin levels. The relationship between leptin level and weight gain associated with neuroleptic drugs has also been investigated. There have been many reports of altered levels of leptin in schizophrenic patients; some studies reported decreased serum leptin levels in schizophrenic patients, but others have found increased levels. Leptin levels have been shown to correlate with hyperactivity in starved animals. Amenorrhea, which is one of the most common symptoms of AN in female patients, is probably secondary to the decrease in adipose tissue, but may be directly associated with very low serum leptin levels. It has been shown that a serum leptin level less than 1.85 mcg/L predicts amenorrhea and subnormal serum levels of LH in AN. Weight restoration therapy does not reverse amenorrhea in all patients and it has been reported that in these cases leptin levels remain lower than in healthy controls. Comorbid depressive symptoms are another characteristic of AN. Evidence indicates that there is a bidirectional relationship between depression and metabolic dysregulation. Leptin receptors have been found in the limbic system, and leptin also has been shown to affect hippocampal and cortical structures through its effects on neurogenesis, axon growth, synaptogenesis and dendritic morphology. Low levels of leptin are associated with depressive behaviors and exposure to chronic stress decreases serum leptin. A recent study of therapy for AN reported a reduction in depressive symptoms measured with Beck Depression Inventory and Hamilton depression Rating Scale following increases in BMI and leptin serum levels. This suggests that there may be a direct association between leptin concentration balance and depressive symptoms. Leptin may serve as biomarker for depression in general, or in depressed patients with altered metabolic function.

Increased dopamine level in nucleus accumbens accompanying obesity is supposed to influence disorders such as anxiety, depression and may affect neurocognitive functions. It is commonly believed, although there is no definitive proof, that appetite modulators also affect non-homeostatic cognitive, emotional and reward factors involved in regulation of food intake. The most common disorders associated with disturbance of metabolic state regulators are AN and bulimia nervosa (BN). AN and BN are classified as EDs of complex and still unknown etiology. AN is characterized by low leptin levels. Data on leptin levels in leptin in the BN are inconsistent; it is possible that leptin levels may be vary according to the phase of the disease or the severity of symptoms. In AN patients levels of leptin are similar to those seen in healthy controls and lower than in healthy controls. Leptin levels have been shown to correlate with BMI and leptin serum levels. This suggests that there may be a direct association between leptin concentration balance and depressive symptoms. Leptin may serve as biomarker for depression in general, or in depressed patients with altered metabolic function.

Early research on the role of leptin in schizophrenia explored the impact of treatment with antipsychotics on leptin levels. The relationship between leptin level and weight gain associated with neuroleptic drugs has also been investigated. There have been many reports of altered levels of leptin in schizophrenic patients; some studies reported decreased serum leptin levels in schizophrenic patients, but others have found increased serum leptin levels in antipsychotic-naïve female patients with schizophrenia. The neurobiological basis of schizophrenia is not fully understood but dopamine abnormalities in this disease have been extensively investigated. On animal model there is postulated theory of increased dopamine level in nucleus accumbens...
in schizophrenic rats. Leptin may modulate dopaminergic activity through leptin receptor-expressing neurons in the mesolimbic pathway\(^{[90]}\). It has been reported that leptin reduces mesolimbic dopaminergic activity and decreases dopamine levels in the nucleus accumbens\(^{[90][91]}\). This is consistent with studies which have reported a negative correlation between leptin levels and severity symptoms in schizophrenia\(^{[93]}\) and may indicate that leptin is involved in negative feedback to counteract increased dopamine activity in the brain\(^{[91]}\). However other study noted higher plasma levels of leptin in schizophrenic patients than in healthy controls\(^{[92]}\).

### RESISTIN

Resistin was discovered in 2001; it is a peptide and is also known as adipose tissue-specific secretory factor or C/EBP-epsilon-regulated myeloid-specific secreted cytokine-rich protein (XCP1). It is considered a pro-inflammatory factor and is thought to be resistant to insulin\(^{[93]}\). Adipocytes are the main source of resistin in the human body, but expression of resistin is also high in mononuclear blood cells.

Recently researchers suggested that there is an association between inflammatory agents produced by adipose tissue and risk of depression\(^{[10]}\). Some studies have reported a positive correlation between resistin concentration in the blood and atypical, melancholic subtypes of major depressive disorders\(^{[93][94]}\). This association may be related to the reduction in intrasynaptic concentration of monoamines by resistin via inhibition of release of norepinephrine and dopamine in the hypothalamus\(^{[96]}\).

It has been suggested that resistin is involved in the pathogenesis of bipolar disorder (BD). Insulin resistance is one of the main etiological factors in BD. Resistin activates enzymes involved in gluconeogenesis and increases glycogenolysis, thereby contributing to hepatic insulin resistance by decreasing the expression of GLUT 4. A recent study reported increased levels of resistin in patients with BD, the specific role of resistin in the pathogenesis of the illness is still unknown\(^{[97]}\). Reduced concentration of resistin have been observed in patients with obsessive compulsive disorder\(^{[98]}\), similarly lower levels of serum resistin have been observed in patients with ASDs\(^{[99]}\) and EDs\(^{[100]}\). Low resistin levels in EDs could be due to downregulation of mononuclear macrophage levels and/or a reduction in pro inflammatory processes\(^{[108]}\).

### OTHER ADIPOKINES

The well-known adipokines are discussed above, but there are over 600 less well-known adipokines which are extensively involved in human physiology and pathology. Some adipokines are involved in the regulation of metabolism (e.g., dipeptyl peptidase 4, vasin, visfatin, chemerin), others in the immune response (e.g., adipin, ASP, SAA3, interleukin (IL)-17D, colony-stimulating factors], inflammation (e.g., IL-1β, IL-6, IL-8, IL-10, C-reactive protein, monocyte chemoattractant protein-1, osteopontin, progranulin, chemerin), hypertension (e.g., angiotensinogen), cell adhesion (e.g., plasminogen activator inhibitor-1), adipogenesis and bone morphogenesis (e.g., bone morphogenetic protein-7), cell or tissue growth (e.g., insulin-like growth factor-1, transforming growth factor beta, fibronectin, fibroblast growth factor 21, vascular endothelial growth factor) and many others functions\(^{[101][108]}\). Some adipokines have multidirectional actions or interplay with other molecules in a variety of functions. These data urgent to define their function and potential clinical relevance in health and disease, also in mental disorders.

Few attempts have been already done. There was no significant association between the concentration of circulating visfatin and presence of EDs\(^{[101][104]}\). Recent studies have shown reliance between starvation and decrease plasma level of adipin, which suggests possible role of this peptide in etiology of AN\(^{[111]}\). Serum levels of omentin were normal in drug-naive patients with major depression\(^{[112]}\). These negative results should not dissuade researchers from investigating the role of adipokines in mental disorders.

### CONCLUSION

The studies discussed here provide evidence that disturbances in adipokine secretion are important in the pathogenesis, clinical presentation and outcome of mental disorders. There is a consensus that leptin and adiponectin are associated with symptoms of depression. Changes in the physiology of appetite modulators in EDs play a pivotal role in motivated behaviors, reward processes and energy balance. Sometimes, as in AN, secondary downregulation of adipokines has a significant impact on the symptoms and course of a disorder. A better understanding of the endocrine function of adipose tissue would have a significant impact on understanding of mental disorders and would lead to more rational therapies for these diseases. There is a lack of research into the role of adipokines in different mental disorders; this is an area which warrants further research. Detailed investigation of links between adipokines and mental disorders is still a new topic in psychiatric research.

### REFERENCES

1. **Zhang Y**, **Proença R**, **Maffei M**, **Barone M**, **Leopold L**, **Fargnoli JL**, **Williams CJ**, **Li T**, **Willett W**, **Kawachi I**, **Qi L**, **Hu FB**, **Mantzoros CS**. Phobic anxiety is associated with higher serum concentrations of adipokines. *Nature* 1994; 372: 425-432 [PMID: 7984236]

2. **Beumer W**, **Drexhage RC**, **De Wit H**, **Versnel MA**, **Drexhage HA**, **Cohen D**. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. *Psychoendocrinology* 2012; 37: 1901-1911 [PMID: 22541717 DOI: 10.1016/j.psy-neu.2012.04.001]

3. **Brennan AM**, **Fargnoli JL**, **Williams CJ**, **Li T**, **Willet W**, **Kawachi I**, **Qi L**, **Hu FB**, **Mantzoros CS**. Phobic anxiety is associated with higher serum concentrations of adipokines.
and cytokines in women with diabetes. *Diabetes Care* 2009; 32: 926-931 [PMID: 19223611 DOI: 10.2337/dc08-1979]

4 Warren MP. Endocrine manifestations of eating disorders. *J Clin Endocrinol Metab* 2011; 96: 333-343 [PMID: 21159848 DOI: 10.1210/jc.2011-0920]

5 Koo M, Lai NS, Chiang JR. Short duration of sleep is associated with hyperleptinemia in Taiwanese adults. *J Clin Sleep Med* 2013; 9: 1049-1055 [PMID: 24172149 DOI: 10.5664/jcsm.3080]

6 Warren MW, Hyman LS, Weiner MF. Lipids and adipokines as risk factors for Alzheimer’s disease. *J Alzheimers Dis* 2012; 29: 151-157 [PMID: 22232009 DOI: 10.3235/JAD-2012-111385]

7 Ahima RS, Flier JS. Leptin. *Annu Rev Physiol* 2000; 62: 413-437 [PMID: 10845097]

8 Nillni EA, Vaslet C, Harris M, Hollenberg A, Bjerkab C, Flier JS. Leptin regulates prothrytotropin-releasing hormone biosynthesis. Evidence for direct and indirect pathways. *J Biol Chem* 2000; 275: 3612-3613 [PMID: 10676095]

9 Rybakowski F, Slopian A, Tyszkiwcz-Niwafo M. Inverse relationship between leptin increase and improvement in depressive symptoms in anorexia nervosa. *Neuro Endocrinol Lett* 2014; 35: 64-67 [PMID: 24629515]

10 Beumer W, Gibney SM, Drexhage RC, Pont-Lezica L, Doorduin J, Klein HC, Steiner J, Connor TJ, Harkin A, Versneld MA, Drexhage HA. The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. *J Leukoc Biol* 2012; 92: 959-975 [PMID: 22878882 DOI: 10.1189/jlb.0212110]

11 Shelton RC, Miller AH. Inflammation in depression: is adiposity a cause? *Dialogues Clin Neurosci* 2011; 13: 41-53 [PMID: 21485745]

12 Coelho R, Viola TW, Wals-Bass C, Brietzke E, Grassi-Oliveira R. Childhood maltreatment and inflammatory markers: a systematic review. *Acta Psychiatr Scand* 2014; 129: 180-192 [PMID: 2420846 DOI: 10.1111/acps.12217]

13 Song X, Fan X, Song X, Zhang J, Zhang W, Li X, Gao J, Hannig A, Ziedonis D, Lv L. Elevated levels of adiponectin and other cytokines in drug naive, first episode schizophrenia patients with normal weight. *Schizophr Res* 2013; 150: 269-273 [PMID: 23998860 DOI: 10.1016/j.schres.2013.07.044]

14 Eikelis N, Lambert G. The brain and leptin resistance and implications for food-related disorders. In Handbook of Behavior, Food and Nutrition. New York: Springer, 2011: 1301-1315

15 Taylor VH, Macqueen GM. The Role of Adipokines in Understanding the Associations between Obesity and Depression. *J Obes* 2010; pii: 748048 [PMID: 20798882 DOI: 10.1155/2010/748048]

16 Renaldi O, Pramono B, Sinorita H, Purnomo LB, Ailenman SM, Tschöp M, Banks WA. Adiponectin does not cross the blood-brain barrier but modifies cytokine expression of brain endothelial cells. *Diabetes* 2006; 55: 141-147 [PMID: 16380487]

17 Wang HC, Yang YK, Chen PS, Lee IH, Yeh TL, Lu RB. Increased plasma leptin in antipsychotic-naïve females with schizophrenia, but not in males. *Neuropsychobiology* 2007; 56: 216-219 [PMID: 18382119 DOI: 10.1515/00012267]

18 Kraus T, Haack M, Schult A, Hinze-Selch D, Pohlmaecher T. Low leptin levels but normal body mass indices in patients with depression or schizophrenia. *Neuropsychobiology* 2001; 73: 243-247 [PMID: 11340338]

19 Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. *J Biol Chem* 1995; 270: 26746-26749 [PMID: 7959267]

20 Kadowaki T, Yamauchi T, Adiponectin and adiponectin receptors. *Endor Res* 2005; 26: 439-451 [PMID: 15897298]

21 Zimmermann R, Strauss JG, Haemmerle G, Schoiswohl G, Birner-Gruenberger R, Riederer M, Lass A, Neuberger G, Eisenhaber F, Hermetter A, Zechner R. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. *Science* 2004; 306: 1383-1386 [PMID: 15556674]

22 Goldstein BJ, Scalia R. Adiponectin: A novel adipokine linking adipoctyes and vascular function. *J Clin Endocrinol Metab* 2004; 89: 2563-2568 [PMID: 15191024]

23 Tsuchida A, Yamauchi T, Ito Y, Hada Y, Maki T, Takekawa S, Kamon J, Kobayashi M, Suzuki R, Hara K, Kubota N, Terauchi Y, Fuguel P, Nakae J, Kasuga M, Accili D, Tobe K, Ueki K, Nagai R, Kadowaki T. Insulin/FoxO1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. *J Biol Chem* 2004; 279: 30817-30822 [PMID: 15128605]

24 Hug C, Wang J, Ahmad NS, Bogan JS, Tosa TS, Lodish HF. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. *Proc Natl Acad Sci U S A* 2004; 101: 10308-10313 [PMID: 15219037]

25 Kazmi A, Sattar A, Hashim R, Khan SP, Younus M, Khan FA. Serum leptin values in the healthy obese and non-obese subjects of Rawalpindi. *J Pak Med Assoc* 2013; 63: 245-248 [PMID: 23894094]

26 Silha J, Krsek M, Skrzka JV, Sucharda P, Nyomba BL, Murphy IJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. *Eur J Endocrinol* 2003; 149: 331-335 [PMID: 14514348]

27 Whitehead JP. Richards AA, Hickman IJ, Macdonald GA, Prins JB. Adiponectin—A key adipokine in the metabolic syndrome. *Diabetes Obes Metab* 2006; 8: 264-280 [PMID: 16634986]

28 Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an...
adipokine regulating glucose and lipid metabolism. *Trends Endocrinol Metab* 2002; 13: 84-89 [PMID: 11854024]

38 Yamauchi T, Kamon J, Jto Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohzeki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Foguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kodawo T. Cloning of adiponectin receptors that mediate anti diabetic metabolic effects. *Nature* 2003; 423: 762-769 [PMID: 12802337]

39 Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinaemia. *J Clin Endocrinol Metab* 2001; 86: 1930-1935 [PMID: 11344187]

40 Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acp30 enhances hepatic insulin action. *Nat Med* 2001; 7: 974-975 [PMID: 11479628]

41 Lehto SM, Huotari A, Niikanen L, Tolmunen T, Koivumaa-Honkanen H, Honkalampi K, Ruotsalainen H, Herzig KH, Viinamäki H, Hintikka J. Serum adiponectin and resistin levels in major depressive disorder. *Acta Psychiatr Scand* 2010; 121: 209-215 [PMID: 19646209 DOI: 10.1111/j.1600-0447.2009.01463.x]

42 Unsal C, Harirgi AG, Yanartas O, Sevinc E, Atmaca M, Bilici M. Low plasma adiponectin levels in panic disorder. *J Affect Disord* 2012; 139: 302-305 [PMID: 22484202 DOI: 10.1016/j.jad.2012.04.028]

43 Cohn TA, Remington G, Zipsurky RB, Azad A, Connolly P, Wolever TM. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: A preliminary report. *CNS Spectr* 2006; 11: 382-386 [PMID: 16768620]

44 Diniz BS, Teixeira AL, Campos AC, Miranda AS, Rocha NP, Talib LL, Gattaz WF, Forlenza OV. Reduced serum levels of adiponectin in elderly patients with major depression. *J Psychiatr Res* 2012; 46: 1081-1085 [PMID: 22633596 DOI: 10.1016/j.jpsychires.2011.06.013]

45 Rissanen T, Lehto SM, Hintikka J, Honkalampi K, Saharinen T, Viinamäki H, Koivumaa-Honkanen H. Biological and other health related correlates of long-term life dissatisfaction burden. *BMC Psychiatry* 2013; 13: 202 [PMID: 23902899 DOI: 10.1186/1471-244X-13-202]

46 Lo Sauro C, Ravaldi C, Cabras PL, Faravelli C, Ricca V. Stress, hypothalamic-pituitary-adrenal axis and eating disorders. *Neuropsychobiology* 2008; 57: 95-115 [PMID: 18552511 DOI: 10.1159/000103912]

47 Liu J, Guo M, Zhang D, Cheng SY, Liu M, Ding J, Scherer PE, Liu F, Lu XY. Adiponectin is critical in determining susceptibility to depressive behaviors and has antidepressant-like activity. *Proc Natl Acad Sci USA* 2012; 109: 12248-12253 [PMID: 22778410 DOI: 10.1073/pnas.1202835109]

48 Fasshauer M, Klein J, Neumann S, Eslinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. *Biochem Biophys Res Commun* 2002; 290: 1084-1089 [PMID: 11798186]

49 Degawa-Yamauchi M, Moss KA, Bovenkerk JE, Shankar SS, Morrison CL, Lelliott CJ, Vidal-Puig A, Jones R, Considine RV. Regulation of adiponectin expression in human adipocytes: effects of adiposity, glucocorticoids, and tumor necrosis factor alpha. *Obes Res* 2005; 13: 662-669 [PMID: 15897477]

50 Amiitary H, Asakawa A, Ogiso K, Nakahara T, Ushikai M, Harata I, Koyama K, Amiitary M, Cheng KC, Inui A. The role of adiponectin multimers in anorexia nervosa. *Nutrigenomics* 2013; 29: 203-206 [PMID: 23257649 DOI: 10.1016/j.nut.2012.07.011]

51 Kaciński M, Budziszewska B, Lason W, Zając A, Skowronek-Bala B, Leśkiewicz M, Kubik A, Basta-Kaim A. Level of S100B protein, neuron specific enolase, orexin A, adiponectin and insulin-like growth factor in serum of pediatric patients suffering from sleep disorders with or without epilepsy. *Pharmacol Rep* 2012; 64: 1427-1433 [PMID: 23406753]
Koziolek M, Samochowiec J. Association of plasma hormones, nutritional status, and stressful life events in anorexia nervosa patients. *Postepy Hig Med Dosw* (Online) 2014; 68: 162-171 [PMID: 24662784]

71 Müller TD, Föller M, Holtkamp K, Herpertz-Dahlmann B, Hebebrand J. Leptin-mediated neuroendocrine alterations in anorexia nervosa: somatic and behavioral implications. *Child Adolesc Psychiatr Clin N Am* 2009; 18: 117-129 [PMID: 19014861 DOI: 10.1016/j.chc.2008.07.002]

72 Berridge KC. Food reward: brain substrates of wanting and liking. *Neurosci Biobehav Rev* 1996; 20: 1-25 [PMID: 8622814]

73 Keating C, Tilbrook AJ, Rossell SL, Enticott PG, Fitzgerald PB. Reward processing in anorexia nervosa. *Neuropsychobiology* 2012; 50: 567-575 [PMID: 23349445 DOI: 10.1159/000349480 2012.01.036]

74 Kaye WH, Fudge JL, Paulus M. New insights into symptoms and neurocircuit function of anorexia nervosa. *Nat Rev Neurosci* 2009; 10: 573-584 [PMID: 19603056 DOI: 10.1038/nrn2682]

75 Cowley MA, Smart JL, Rubinstein M, Cerdán MC, Diano S, Horvath TL, Cone RD, Low MJ. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. *Nature* 2001; 411: 480-484 [PMID: 11375681]

76 Marais L, Stein DJ, Daniels WM. Exercise increases BDNF levels in the striatum and decreases depressive-like behavior in chronically stressed rats. *Metab Brain Dis* 2009; 24: 587-597 [PMID: 19844781 DOI: 10.1007/s11011-009-9157-2]

77 Mantzoros CS. Role of leptin in reproduction. *Ann N Y Acad Sci* 2000; 908: 174-185 [PMID: 10814040]

78 Chan JL, Mantzoros CS. Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhea and anorexia nervosa. *Lancet* 2005; 366: 74-85 [PMID: 15993236]

79 Brambilla F, Monteleone P, Bortolotti F, Dalle Grave R, Todisco P, Favaro A, Santonastaso P, Ramacciotti C, Paoli R, Maj M. Persistent amenorrhea in weight-recovered anorexics: a pilot study. *Psychoneuroendocrinology* 2003; 118: 249-257 [PMID: 12634819]

80 Penninx BW, Milaneschi Y, Lamers F, Vogelzangs N. Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. *BMC Med* 2013; 11: 129 [PMID: 23676268 DOI: 10.1186/1741-7015-11-129]

81 Schmidt HD, Shelton RC, Duman RS. Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. *Neuropsychopharmacology* 2011; 36: 2375-2394 [PMID: 21814182DOI: 10.1038/npp.2011.151]

82 Rao U. Biomarkers in pediatric depression. *Depress Anxiety* 2013; 30: 787-791 [PMID: 24002798 DOI: 10.1002/dia.22171]

83 Yilmaz Z, Kaplan AS, Tiwari AK, Levitan RD, Piran S, Kaplan AS, Tiwari AK, Levitan RD, Piran S, et al. Antipsychotic therapy on leptin, ghrelin, and adiponectin. *Schizophrenia Res* 2018; 100: 70-75 [PMID: 25317335 DOI: 10.1016/j.schres.2017.11.026]

84 Noori-Daloii MR, Mojarrad M, Rashidi-Nezhad A, Kheiriollahi M, Shahbazi A, Klaksir M, Korzeboeck, Goosardar A, Ebrahimi M. Noori-Daloii AR. Use of siRNA in knocking down of dopamine receptors, a possible therapeutic option in neuropsychiatric disorders. *Mal Biol Rep* 2012; 39: 2003-2010 [PMID: 21633887 DOI: 10.1016/s1103-011-9047-3]

85 Seeman P. Glutamate and dopamine components in schizophrenia. *J Psychiatry Neurosci* 2009; 34: 143-149 [PMID: 19270765]

86 Opland DM, Leinninger GM, Myers MC. Modulation of the mesolimbic dopamine system by leptin. *Brain Res* 2010; 1350: 65-70 [PMID: 20417193 DOI: 10.1016/j.brainres.2010.04.028]

87 Hommel JD, Trinko R, Sears RM, Georgescu D, Liu ZW, Gao XB, Thurmon J, Marinelli M, DiLeone RJ. Leptin receptor signaling in midbrain dopamine neurons regulates feeding. *Neuron* 2006; 51: 801-810 [PMID: 16982424]

88 Krügel U, Schraft T, Kittner H, Kiess W, Illes P. Basal and feeding-evoked dopamine release in the rat nucleus accumbens is depressed by leptin. *Eur J Pharmacol* 2003; 482: 185-187 [PMID: 14660021]

89 Tsai MC, Chang CM, Liu CY, Chang PY, Huang TL. Association of serum levels of leptin, ghrelin, and adiponectin in schizophrenic patients and healthy controls. *Int J Psychiatry Clin Pract* 2011; 15: 106-111 [PMID: 22121858 DOI: 10.3109/13651503.2010.534004]

90 Pang SS, Le YY. Role of resistin in inflammation and inflammation-related diseases. *Cell Mol Immunol* 2006; 3: 29-34 [PMID: 16549046]

91 Weber-Hamann B, Kratzsch J, Kopf D, Lederbogen F, Gilles M, Heuser I, Deuschle M. Resistin and adiponectin in major depression: the association with free cortisol and effects of antidepressant treatment. *J Psychiatr Res* 2007; 41: 344-350 [PMID: 16497334]

92 Zeugmann S, Quinn A, Heuser I, Schwarzer R, Anghelescu I. Inflammatory biomarkers in 70 depressed inpatients with and without the metabolic syndrome. *J Clin Psychiatry* 2010; 71: 1007-1016 [PMID: 20156411DOI: 10.4088/JCP.08m04767blu]

93 Brunetti L, Orlando G, Recinella L, Michelotto B, Ferrante C, Vacca M. Resistin, but not adiponectin, inhibits dopamine and norepinephrine release in the hypothalamus. *Eur J Pharmacol* 2004; 493: 41-44 [PMID: 15189762]

94 Ymuru M, Gergerioglu HS, Savas HA, Basarali K, Kalenderoglu A, Buyukbas S. Serum resistin levels and metabolic changes in bipolar disorder. *Bio Med Res Int* 2012; 4: 27-50 [DOI: 10.5455/jmro.2012.0516040842]

95 Ari M, Ozurtok OH, Bec Y, Arica S, Can Y, Erduran S. Serum adiponectin and resistin levels in patients with obsessive compulsive disorder. *J Affect Disord* 2012; 136: 979-982 [PMID: 22119090 DOI: 10.1016/j.jad.2011.07.029]

96 Rodrigues DH, Rocha NP, Sousa LF, Barbosa IG, Kummer A, Teixeira AL. Changes in adipokine levels in autism spectrum disorders. *Neuropsychobiology* 2014; 69: 6-10 [PMID: 24401207]

97 Dostalova I, Kunesova M, Duskova J, Paapezo H, Nedvidkova J. Adipose tissue resistin levels in patients with anorexia nervosa. *Nutrition* 2006; 22: 977-983 [PMID: 16889937 DOI: 10.1016/j.nut.2006.06.006]

98 Blüher M. Adipokines - removing roadblocks to obesity and diabetes therapy. *Mol Metab* 2014; 3: 230-240 [PMID: 24749053 DOI: 10.1016/j.molmet.2014.01.005]

99 Chaudhri OB, Wynne K, Bloom SR. Can gut hormones control appetite and prevent obesity? *Diabetes Care* 2008; 31 Suppl 2: S284-S289 [PMID: 18272498 DOI: 10.2373/dcb08-269]

100 Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. *Nat Rev Immunol* 2011; 11: 85-97 [PMID: 21252989 DOI: 10.1038/nri2921]

101 Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. *Ann N Y Acad Sci* 2010; 1212, E1-E19 [PMID: 21276002 DOI: 10.1111/j.1749-663
2.2010
105 Yiannikouris F, Gupte M, Putnam K, Cassis L. Adipokines and blood pressure control. *Curr Opin Nephrol Hypertens* 2010; 19: 195-200 [PMID: 20051852 DOI: 10.1097/MNH.0b013e3283366cd0]

106 Isoppo de Souza C, Rosa DD, Ettrich B, Cibeira GH, Giacomazzi J, Tusset P, Ashton-Prolla P, Medeiros LR, Caleffi M, Neto EC, Moriguchi EH, Graudenz MS. Association of adipokines and adhesion molecules with indicators of obesity in women undergoing mammography screening. *Nutr Metab (Lond)* 2012; 9: 97 [PMID: 23113882 DOI: 10.1186/1743-7075-9-97]

107 Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, Muruganandan S, Sinal CJ. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. *J Biol Chem* 2007; 282: 28175-28188 [PMID: 17635925]

108 Scotece M, Conde J, Abella V, López V, Pino J, Lago F, Gómez-Reino JJ, Gualillo O. Bone metabolism and adipokines: are there perspectives for bone diseases drug discovery? *Expert Opin Drug Discov* 2014; 9: 945-957 [PMID: 24657197 DOI: 10.1517/17464426.2014.922539]

109 Dostalova I, Sedilackova D, Papezova H, Nedvidkova J, Haluzik M. Serum visfatin levels in patients with anorexia nervosa and bulimia nervosa. *Physiol Res* 2009; 58: 903-907 [PMID: 19093738]

110 Zioka K, Oswiecimska J, Swietochowska E, Ziora D, Stoeewska M, Suwała A, Ostrowska Z, Gorczyca P, Klimacka-Nawrot E, Lukas W, Blotska-Fajrowska B. Assessment of serum visfatin levels in girls with anorexia nervosa. *Clin Endocrinol (Oxf)* 2012; 76: 514-519 [PMID: 21777266 DOI: 10.1111/j.1365-2265.2011.04181.x]

111 Pomeroy C, Mitchell J, Eckert E, Raymond N, Crosby R, Dalmasso AP. Effect of body weight and caloric restriction on serum complement proteins, including Factor D/adipsin: studies in anorexia nervosa and obesity. *Clin Exp Immunol* 1997; 108: 507-515 [PMID: 9182900]

112 Canan F, Yildirim O, Tosun M, Kayka N, Tuman TC, Alcelik A. Serum levels of omentin are not altered in drug-naive patients with major depression: a pilot study. *Psychiatr Danub* 2014; 26: 34-38 [PMID: 24608150]

P- Reviewer: Kuo WH, Yuan GY  S- Editor: Ji FF  L- Editor: A  E- Editor: Liu SQ
